Core Laboratories (NYSE:CLB) Trading 7.1% Higher - Still a Buy?

Key Points

• Core Laboratories Inc. experienced a 7.1% increase in stock price, trading up to $12.99, despite a significant drop in trading volume.
• Analysts currently hold a consensus rating of "Hold" for Core Laboratories, with price targets ranging from $12.00 to $12.50.
• The company recently declared a quarterly dividend of $0.01 per share, yielding approximately 0.3% annually, highlighting a conservative payout ratio of 6.45%.

Core Laboratories Inc. (NYSE:CLB - Get Free Report) traded up 7.1% during trading on Tuesday . The company traded as high as $12.94 and last traded at $12.99. 60,860 shares were traded during mid-day trading, a decline of 87% from the average session volume of 470,241 shares. The stock had previously closed at $12.13.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CLB. Stifel Nicolaus lowered their price target on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Wall Street Zen upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, Zacks Research upgraded shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $12.50.

Core Laboratories Trading Up 1.1%

The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.70 and a current ratio of 2.27. The company has a 50-day simple moving average of $11.47 and a 200-day simple moving average of $12.16. The stock has a market cap of $575.20 million, a P/E ratio of 19.79, a P/E/G ratio of 3.61 and a beta of 1.46.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $130.16 million for the quarter, compared to analyst estimates of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.Core Laboratories's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. On average, sell-side analysts forecast that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 25th. Stockholders of record on Monday, August 4th were given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, August 4th. Core Laboratories's payout ratio is 6.45%.

Institutional Investors Weigh In On Core Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC grew its holdings in Core Laboratories by 265,800.0% during the 1st quarter. AlphaQuest LLC now owns 2,659 shares of the oil and gas company's stock valued at $40,000 after purchasing an additional 2,658 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Core Laboratories by 92.5% in the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock valued at $43,000 after purchasing an additional 1,387 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Core Laboratories by 400.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,333 shares of the oil and gas company's stock worth $84,000 after acquiring an additional 5,869 shares in the last quarter. Ingalls & Snyder LLC purchased a new stake in shares of Core Laboratories during the 2nd quarter worth approximately $115,000. Finally, BNP Paribas Financial Markets purchased a new position in Core Laboratories during the 4th quarter worth $123,000. Hedge funds and other institutional investors own 97.81% of the company's stock.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.